炒股”倒亏2亿元！双鹭药业董事长自掏腰包填“窟窿

Core Viewpoint - The company, Shuanglu Pharmaceutical, is expected to continue its losses in 2025, projecting a net profit attributable to shareholders of between -290 million to -200 million yuan, representing a year-on-year decline of 291.54% to 170.03% from the previous year's loss of 74.07 million yuan [1][2]. Financial Performance - The projected net profit for 2025 is between -290 million to -200 million yuan, a significant decline compared to the previous year's loss of 74.07 million yuan [1][2]. - The expected non-recurring net profit for 2025 is between -70 million to -40 million yuan, down 185.02% to 148.58% from the previous year's profit of 82.34 million yuan [1][2]. - Basic earnings per share are projected to be -0.28 yuan, compared to -0.07 yuan in the previous year [2]. Reasons for Performance Decline - The decline in performance is attributed to two main factors: a decrease in product prices due to industry policy adjustments and market competition, leading to a 10% drop in sales gross margin [2]. - Non-recurring losses, particularly from investment losses and fair value changes in financial assets, are expected to reduce net profit by approximately 200 million yuan [2][3]. Investment Losses and Management Actions - The company has confirmed investment losses, which it is attempting to recover through various means. The chairman has voluntarily committed to cover any irrecoverable losses, initially contributing 50 million yuan to the company [3]. - The company maintains sufficient cash reserves and normal operational activities, indicating that these issues will not affect other business operations [3]. Financial Asset Impact - Financial asset investments have become a "double-edged sword" for the company, with significant fluctuations in stock prices of holdings like Fosun Pharma and others leading to a net profit reduction of 178 million yuan in 2024 [4]. - In the first three quarters of 2025, the company reported a net profit of 141 million yuan, a year-on-year increase of 943.10%, primarily due to fair value changes in financial assets [4]. Gross Margin Trends - The company's gross margin has been declining, from 81.56% in 2023 to 67.97% in 2024, and further down to 61.60% in the first three quarters of 2025 [6]. Company Background - Shuanglu Pharmaceutical, established in December 1994 and listed in September 2004, is a high-tech enterprise with over 70 products, including three Class I new drugs, focusing on areas such as blood, oncology, cardiovascular, liver disease, diabetes, and kidney disease treatments [8].